Angiogenesis and its association with inflammation and fibrosis in the course of scleroderma systematica

Close metadata

Recommended articles:

Peculiarities of angiogenesis in clear cell renal cancer. Russian Journal of Archive of Pathology. 2024;(4):64-70

Influence of perioperative pharmacological stimulation of angiogenesis with 5-oxymethyluracil on long-term results of myocardial revascularization. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):22-28

Secretome of mesenchymal stromal cells of the human heart cultured in the form of spheroids is enriched with angiogenic factors and stimulates angiogenesis in vitro and in vivo. Russian Cardiology Bulletin. 2024;(1):38-46

Endothelial cells control vascular growth via regulation of Notch signaling pathway in mesenchymal stromal cells. Russian Cardiology Bulletin. 2024;(2):32-38

Predicting the risk of decreased ovarian reserve after surgical treatment of patients with deep infiltrative endometriosis using artificial intelligence. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):92-102

Scleroderma systematica (SDS) is a chronic autoimmune disease characterized by severe fibrosis of the skin and visceral organs. Vascular disorders are an important component of the disease, but the mechanisms of vascular injury and their prevention are unknown. Angiogenesis in SDS is accompanied by the apparent expression of angiogenic factors, such as vascular endothelial growth factor and basal or fibroblast growth factor. Imbalance of these markers with endostatin expression is noted. This disease is characterized by inflammation and the intensity of neoangiogenesis correlates with its activity. The fact that there may be a pathogenic relationship between the processes of angiogenesis and the intensity of further fibrosis is shown. There is a vicious circle of the induction and maintenance of the processes of angiogenesis, inflammation, and fibrosis in SDS.

Keywords:

scleroderma systematica

vascular disorders

angiogenesis

angiogenic markers

angiostatic markers

Authors:

Radenska-Lopovok S.G.

FGBU "Nauchno-issledovatel'skiĭ institut revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Korzenyova E.G.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Alekperov R.T.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

List of references:

von Bierbrauer A.F., Mennel H.D., Schmidt J.A., von Wichert P. Intravital microscopy and capillaroscopically guided nail fold biopsy in scleroderma. Ann. Rheum. Dis. 1996; 55 (5): 305—10.
Kuiper E.J., Hughes J.M., Van Geest R.J., Vogels I.M., Goldschmeding R., Van Noorden C.J. et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest. Ophthalmol. Vis. Sci. 2007; 48: 4267—76.
Takahashi M., Yamamoto M., Kunugi Sh. et al. Significance of angiogenesis in intra-alveolar fibrosis in interstitial pneumonia. J. Nippon Med. Sch. 2008; 75 (1): 48—9.
Distler O., Del Rosso A., Giocomelli O., Cipriani P., Conforti M.L., Guiducci S. et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a future of the earliest disease stages and are associated with the absence of fingertips ulcers. Arthritis Res. 2002; 4: R11.
Distler J. H., Jüngel A., Pileckyte M., Zwerina J., Michel B.A., Gay R.E. et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007; 56 (12): 4203—15.
Kuryliszyn-Moskal A., Klimiuk P.A., Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin. Rheumatol. 2005; 24: 111—6.
Hong K.-H., Yoo S.A., Kang S.S., Choi J.J., Kim W.U., Cho C.S. Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblast. Clin. Exp. Immunol. 2006; 146: 362—70.
Distler J.H., Akhmetshina A., Dees C., Jüngel A., Stürzl M., Gay S. et al. Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis Rheum. 2011; 63 (7): 2067—77.
Lawrence A., Khanna D., Misra R., Aggarwal A. Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis. Dermatol. Online J. 2006; 12 (1): 2.
Del Papa N., Cortiana M., Comina D.P. Endothelial progenitor cells in systemic sclerosis: their possible role in angiogenesis. Reumatismo. 2005; 57 (3): 174—9.
Distler J.H., Wenger R.H., Gassmann M., Kurowska M., Hirth A., Gay S. et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2004; 50 (1): 10—23.
Nagashima M., Wauke K., Hirano D., Ishigami S., Aono H., Takai M. et al. Effect of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology. 2000; 39: 1255—62.
Buckland J. Psoriasis: Anti-VEGF antibody therapy for psoriasis? Nat. Rev. Rheumatol. 2010; 6: 119. doi:10.1038/nrrheum.2010.8
Goldring M.B., Marcu K.B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res. Ther. 2009; 11: 224. doi:10.1186/ar2592.
Maumus M., Guérit D., Toupetet K., Jorgensen Ch., Noël D. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res. Ther. 2011; 2: 14.
Mulligan-Kehoe M.J., Drinane M.C., Mollmark J., Shipman S., Buitendijk M., Simons M. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 2007; 56: 3448—58.
Hebbar M., Peyrat J.-Ph., Hornez L., Hatron P., Hachulla E., Devulder B. Increased concentrations of circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000; 43 (4): 889—93.
Dziankowska-Bartowiak B., Waszczykowska E., Zalewska A., de Graft-Johnson J.E., Zalewska A., Luczyn´ska M. et al. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis — associ. Clin. Exp. Rheumatol. 2006; 24: 508—13.
Dziankowska-Bartkowiak B., Waszczykowska E., Zalewska A., Sysa-Jedrzejowska A. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm. 2005; 2005 (3): 144—9.
Cutolo M., Pizzorni C., Secchi M.E., Sulli A. Capillaroscopy. Breast Pract. Res. Clin. Rheumatol. 2008; 22 (6): 1093—8.
Distler O., Scheid A., Rosso A., Rethage J., Neidhartet M. HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc. Arthritis Res. 2002; 4 (Suppl. 1): 1.
Distler O., Scheid A., Rosso A., Rethage J., Neidhartet M. HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc. Arthritis Res. 2002; 4 (Suppl. 1): 1.
Sysa-Jedrzejowska A., Zalewska A., Dziankowska-Bartowiak B., Waszczykowska E. Evaluation of serum vascular endothelial growth factor and endostatin in systemic sclerosis patients — correlation with lung and cardio-vascular system involvement. Centr. Eur. J. Immunol. 2004; 29 (1): 15—22.
Zhukov N.V. Sovremennoe sostoyanie antiangiogennoi terapii. Tselevaya terapiya bez misheni? Prakticheskaya onkologiya. 2007; 8 (3): 164—72.
Szekanecz Z., Koch A.E. Vascular involvement in rheumatic diseases: «Vascular rheumatology». Arthritis Res. 2008; 10 (5): 224—34.
Saidov M.Z., Nasonova V.A., Osmanov A.O., Mamaev I.A., Radenska-Lopovok S.G., Nasonov E.L. Immunogistokhimicheskoe izuchenie angiogeneza pri revmatoidnykh sinovitakh i otsenka ego patogeneticheskogo znacheniya. Immunologiya. 2002; 23 (2): 93—6.
Maruotti N., Cantatore F.P., Nico B., Vacca A., Ribatti D. Angiogenesis in vasculitides. Clin. Exp. Rheumatol. 2008; 26: 476—83.
Roback E., Sysa-Jedrzejewska A., Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm. 2003; 12 (5): 293—8.
Drouart M., Saas P., Billot M. High serum endothelial growth factor correlates with disease activity of spondyloartropathies. Clin. Exp. Immunol. 2003; 132: 158—62.
Salcedo Mora X., Sanz-Cameno P., Medina J., Martin-Vichez S., Garcia-Buey L., Borque M.J. et al. Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients. Rev. Esp. Enferm. Dig. (Madrid). 2005; 97 (10): 699—706.
Hirota S.A., Beck P.L., MacDonald J.A. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. Recent Pat. Inflamm. Allergy Drug Discov. 2009; 3 (1): 1—16.
El Awad B., Kreft B., Wolber E.M., Hellwig-Bürgel T., Metzen E., Fandrey J. et al. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 2000; 58 (1): 43—50.
Yamakawa M., Liu L.X., Date T., Belanger A.J., Vincent K.A., Akita G.Y. et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res. 2003; 93 (7): 664—73.
Muz B., Khan M. N., Kiriakidis S., Paleolog E.M. Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res. Ther. 2009; 11 (1): 201.
Hirota S.A., Beck P.L., MacDonald J.A. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. Recent Pat. Inflamm. Allergy Drug Discov. 2009; 3 (1): 1—16.
El Awad B., Kreft B., Wolber E.M., Hellwig-Bürgel T., Metzen E., Fandrey J. et al. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 2000; 58 (1): 43—50.
Simler N.R., Brenchley P.E., Horrocks A.W., Greaves S.M., Hasleton P.S., Egan J.J. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax. 2004; 59: 581—5.
Serov V.V., Shekhter A.B. Soedinitel'naya tkan' (funktsional'naya morfologiya i obshchaya patologiya). M.: Meditsina; 1981. 312 c.
Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214: 199—210.
Khalil N., Whitman C., Zuo L., Danielpour D., Greenberg A.H. Regulation of alveolar macrophage transforming growth factor-β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J. Clin. Invest. 1993; 92: 1812—8.
Robertson H., Ali S., McDonnell B.J., Burt A.D., Kirby J.A. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J. Am. Soc. Nephrol. 2004; 15: 390—7.
Bates R.C., Arthur M. Tumor necrosis factor- stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol. Biol. Cell. 2003; 14: 1790—800.
Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J. et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 2000; 11 (1): 25—38.
Wallace W.A., Howie S.E. Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. J. Pathol. 1999; 187 (4): 475—80.
Weng H.L., Liu Y., Cheng J.L. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology. 2009; 50 (1): 230—43.
Fuschiotti P., Medsger T.A., Morel P.A. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 2009; 60 (4): 1119—28.
Parel Y., Aurrand-Lions M., Scheja A., Dayer J.M., Roosnek E., Chizzolini C. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum. 2007; 56 (10): 3459—67.
Schmidt K., Martinez-Gamboa L., Meier S. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res. Ther. 2009; 11 (4): R111.
Edmé J.L., Tellart A.S., Launay D. Cytokine concentrations in exhaled breath condensates in systemic sclerosis. Inflamm. Res. 2008; 57 (4): 151—6.
Hancock A., Armstrong L., Gama R., Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am. J. Respir. Cell Mol. Biol. 1998; 18 (1): 60—5.
Strieter R.M. Mechanisms of pulmonary fibrosis. Chest. 2001; 120: S77—85.
Kawai M., Masuda A., Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum. 2008; 58 (11): 3562—73.
Guiducci S., Distler J.H., Milia A.F., Miniati I., Rogai V., Manetti M. et al. Stiff skin syndrome: evidence for an inflammation-independent fibrosis? Rheumatology (Oxford). 2009; 48 (7): 849—52.

Close metadata